Shots:
- The US FDA has approved Onswik (insulin efsitora alfa-gobe) along with diet and exercise to control high blood sugar in adults with type 2 diabetes
- Approval was based on the P-III (QWINT) trials, which evaluated Onswik (QW) in >3,400 adults with T2D; across each trial, Onswik met the 1EP, demonstrating non-inferior A1C reductions vs insulin glargine U-100 or insulin degludec U-100.
- The Onswik KwikPen is expected to launch in the US in the coming mos. in 2 concentrations: 500 units/mL (1,500 units total) & 1,000 units/mL (3,000 units total)
Ref: PRnewswire | Image: Eli Lilly | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
